Abstract
As mentioned in the comment, we provide correlative evidence relating neoadjuvant chemotherapy (NAC) to improve overall survival in patients with upper tract urothelial cancer (UTUC). We agree entirely that given recent evidence supporting use of adjuvant cisplatin-based therapy,1 there is a compelling argument to be made for NAC in high-grade UTUC, particularly given postoperative renal function decline following nephroureterectomy.2,3
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
